HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate HCW Biologics signed license agreement with WY Biotech

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights Press release for Q3 2024 business highlights and financial results

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights Earning release for Q1 2024

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights Q4 and Year End Earnings Release and Business Highlights

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...